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Abstract
Background: Scar burden by late gadolinium enhancement (LGE) cardiovascular magnetic resonance (CMR)
is associated with functional recovery after coronary artery bypass surgery (CABG). There is limited data on long-term
mortality after CABG based on left ventricular (LV) scar burden.
Methods: Patients who underwent LGE CMR between January 2003 and February 2010 within 1 month prior to CABG
were included. A standard 16 segment model was used for scar quantification. A score of 1 for no scar, 2 for ≤ 50 %
and 3 for > 50 % transmurality was assigned for each segment. LV scar score (LVSS) defined as the sum of segment
scores divided by 16. All-cause mortality was ascertained by social security death index.
Results: One hundred ninety-six patients met the inclusion criteria. 185 CMR studies were available. History of prior MI
was present in 64 % and prior CABG in 5.4 % of patients. Scar was present in 72 % of patients and median LVEF was
38 %. Over a median follow up of 8.3 years, there were 64 deaths (34.6 %). There was no statistically significant
difference in mortality between Scar and No-scar groups (37 % versus 29 %). In the group with scar, a lower scar
burden (defined either < 4 segments with scar or based on LVSS) was independently associated with increased survival.
Conclusion: In patients undergoing surgical revascularization, scar burden is negatively associated with survival
in patients with scar. However, there is no difference in survival based on presence or absence of scar alone.
CMR prior to CABG adds additional prognostic information.
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Background
Coronary artery bypass graft surgery (CABG) is one
of the most common cardiac surgeries performed
worldwide. The decision for surgical revascularization
is based on several factors including patient charac-
teristics, coronary anatomy and presence of ischemia
or infarct. Cardiovascular Magnetic Resonance (CMR)
is considered gold standard for assessment of fibrosis/
scar and is commonly used in evaluation of patients
with significant coronary artery disease (CAD) and
cardiomyopathy prior to formulating treatment strategy.
Assessment of size and extent of scar or fibrosis by
Late Gadolinium Enhancement (LGE) by CMR is accur-
ate and reproducible [1–5]. The presence and amount of
LGE is an independent predictor of cardiovascular out-
comes and mortality in patients with ischemic heart fail-
ure (HF) and non-ischemic cardiomyopathies (NICM)
[6–8]. LGE is effective in detection and assessment of
both acute and chronic myocardial infarction (MI) and
is well matched to the perfusion territory of infarct* Correspondence: krish.kancharla@gmail.com
1Department of cardiology, Mayo Clinic, Rochester 55905, MN, USA
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kancharla et al. Journal of Cardiovascular Magnetic Resonance  (2016) 18:45 
DOI 10.1186/s12968-016-0265-y
related artery [9]. In patients with CAD, LGE is a pre-
dictor of major adverse cardiac events (MACE) and
mortality beyond common clinical factors or coronary
anatomy and is independent of left ventricular ejection
fraction (LVEF) [10–13].
In ischemic HF, the transmurality of the scar is nega-
tively associated with functional recovery. Segments
with > 50 % scar have a low probability of functional re-
covery [14–16]. The presence of ≥ 10 segments without
scar or with <50 % transmural scar predicted a global
functional recovery in one study [17] while the pres-
ence of ≤4 scar segments predicted global functional re-
covery after CABG in another study [18]. In patient
with ischemic HF observational studies support
improved survival with CABG over medical therapy
during 10 year follow up [19, 20] while a more recent
randomized study showed a reduction in cardiac mor-
tality but no difference in all-cause mortality [21, 22].
In a cohort of patients treated with CABG, the presence
of larger end systolic volume index and scar burden on
CMR was noted to derive survival benefit compared to
treatment with medical therapy alone [23].
While there is data to support functional improvement
post revascularization, there is limited data in the use of
CMR in outcomes after revascularization. In this study,
we evaluated the association between LGE burden and
long-term mortality after CABG.
Methods
Patients who underwent CMR with LGE between January
2003 and February 2010 within 1 month prior to CABG
surgery were included.
A comprehensive surgical database maintained at our in-
stitution was accessed to obtain demographic, clinical and
surgical information. Angiographic data including major
and branch vessel stenosis was collected. All-cause mortal-
ity was ascertained by social security death index search.
CMR protocol and analysis
Patients were positioned supine in a clinical 1.5 T MR
scanner (CV Intera, Philips, Best, The Netherlands). All
images were acquired using a cardiac phased-array
receiver coil during breath-holds (≈8 s), together with
respiratory and cardiac gating. Cine images were acquired
through the entire left ventricle using 6-mm-thick slices
to minimize the effects of partial volume. LGE images
were obtained after intra venous contrast agent adminis-
tration (0.2 mmol/kg gadolinium dimeglumine, until July
2006, then 0.1 mmol/kg gadobenate dimegluine) [2] using
a segmented inversion-recovery sequence, with an in-
plane spatial resolution of 1.3 to 1.7 mm [1].
Evaluation of CMR and post-processing were per-
formed on a commercially available workstation (View
Forum, Philips Medical Systems). End-diastolic and end-
systolic cardiac contours were traced manually on the
series of LV short-axis cine slices to obtain LVEF and LV
volumes. Scar quantification was performed by image re-
view by an experienced observer who was blinded from
clinical analysis and prior CMR reading. Based on the
prior data on functional improvement after revasculari-
zation in patients with LGE by CMR, a simplified quan-
tification method was used. Left ventricular (LV) was
divided into a standard 16 segment model (6 basal, 6
mid and 4 apical segments) for quantification of scar.
The number of segments with scar was recorded.
Each segment was then scored based on scar trans-
murality. Segment was assigned a score of 1 for no
scar, 2 for ≤50 % thickness, and 3 for > 50 % thickness
or micro vascular obstruction (MVO) (Fig. 1). Subjects
were divided into <4 segments of scar (group A) and ≥4
segments of scar (group B). LV scar score (LVSS) was cal-
culated by the sum of the scores of all segments divided
by 16 [10] (a LVSS of 1 would represent no scar).
Statistical analysis
Data analysis was performed using SAS 9.3 Institute
Inc., Cary, NC, USA. Categorical variables were pre-
sented as proportions and analyzed with Chi square test
(Fisher’s exact test was used in case of small numbers).
For comparison between continuous variables two sam-
ple t- test was used. Non-parametric Wilcoxon rank
sum test was used in case of non-normal variables.
Fig. 1 LGE on CMR in 3 different patients. a- No scar, b- Less than 50 % thickness involvement in multiple segments and c- More than 50 %
thickness involvement in multiple segments
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Univariate and multivariate analysis was performed with
Cox proportional hazard model. Multivariate analysis
was performed using variables that have significant asso-
ciation in the bivariate analysis. Survival probability was
plotted with Kaplan Meier curves (Log rank test). A
value of p < 0.05 was considered statistically significant.
Results
One hundred ninety-six patients met the inclusion cri-
teria. 185 CMR studies were available. The median time
from CMR study to CABG surgery was 2 (1, 4) days. The
mean age of the study population at the time of surgery
was 63.2 years (±11.5). Seventy-two percent were male
and 66 % were Caucasians. History of prior MI was
present in 64 % of patients and prior CABG in 5.4 %
patients. All patients in the study group had signifi-
cant stenosis (≥70 %) in at least one major epicardial
vessel. There was a median of 2 (1,3) significantly stenosed
vessels and 1 (0,1) total occlusions. All patients were
deemed appropriate for CABG as the revascularization
strategy by the angiographer and patient’s cardiologist due
to the presence of complex coronary artery disease. A me-
dian of 4 (3, 4) vessels (major or branch vessels) were
bypassed. Scar was present in 72 % of patients and median
LVEF was 38 % (28, 52). Over a median follow up of
8.3 years (7, 10), there were 64 deaths (34.6 %) in the en-
tire group.
Patients were categorized into Scar group and No-scar
groups. Scar group was further categorized into two groups
based on the number of segments with scar (<4 segments
versus ≥4 segments with scar) and also into three groups
based on LV scar score (LVSS 1–1.24, LVSS 1.25–1.42 and
LVSS >1.42).
Scar versus No-scar group
There were 133 patients in the scar group and 52 pa-
tients in the No-scar group. The baseline characteris-
tics are shown in Table 1. Patients in Scar group had
Table 1 Baseline characteristics of patients at the time of CABG
Parameter All patients Mean/Median (IQ)/% No-scar Mean/Median (IQ)/% Scar group Mean/Median (IQ)/% p value
Number of patients 185 52 133
Age (years) 63.2 (11.5) 64.2 (9.7) 62.8 (12.2) 0.47
Male (%) 71.9 55.8 78.2 0.002
Body Mass Index(BMI) 28.3 (5.1) 28.0 (5.8) 28.4 (4.8) 0.60
History Of Smoking (%) 63.2 57.7 65.4 0.33
Diabetes Mellitus (%) 34.6 25.0 38.3 0.09
Hypertension (%) 78.4 76.9 78.9 0.76
History of Prior MI (%) 63.8 38.5 73.7 <0.0001
Cerebrovascular Disease (%) 14 15.4 13.5 0.75
Peripheral artery disease (%) 20 23.1 18.8 0.5130
Dyslipidemia (%) 70.8 65.4 72.9 0.31
Previous CABG history (%) 5.4 0.0 7.5 0.06
Glomerular filtration rate 68.32 (25.20) 66.0 (25.7) 69.2 (25.0) 0.44
Chronic Lung Disease (%) 17.8 21.1 16.5 0.46
B - Blocker (%) 78.9 73.1 81.2 0.2232
ACE - Inhibitor (%) 56.8 51.9 58.7 0.4067
Aspirin (%) 91.4 86.5 93.2 0.1548
Lipid lowering therapy (%) 71.6 64.3 74.8 0.2076
LVEDV (ml) 210.75 (77.79) 195.44 (86.20) 216.82 (73.65) 0.0936
LVESV (ml) 134.29 (77.40) 118.88 (86.76) 140.40 (72.80) 0.0899
ESVi (ml/m2) 29.77 (18.53, 46.19) 24.67 (12.62, 41.66) 32.39 (19.84, 46.98) 0.0424
LVEF (%) 38 (28,52) 45 (25,65) 37 (28,49) 0.038
Number of Segments scar 2 (0,5) 0 3 (2,6) NA
STS % mortality risk 1.4 (0.8,2.8) 1.4 (0.7,2.6) 1.4 (0.7,2.9) 0.71
Cardiopulmonary Bypass (%) 63.8 61.5 64.7 0.6911
Number of vessels bypassed 4 (3–4) 3.5 (2–4) 4 (3–4) 0.5929
MI Myocardial Infarction, ACE Inhibitor = Angiotensin convertase enzyme Inhibitor, LVEDV left ventricular end diastolic volume, LVESV left ventricular end systolic
volume, ESVi end systolic volume index, LVEF left ventricular ejection fraction, STS society of thoracic surgery
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statistically higher proportion of men (78 % vs. 56 %
(p = 0.002)), history of prior MI (74 % vs. 38 % (p < 0.0001))
and lower percent LVEF (39 % versus 45 % (p = 0.038))
compared to patients in the No-scar group. During
the follow up there was no statistically significant dif-
ference (Fig. 2) in long-term mortality between Scar
and No-scar groups (37 % versus 29 %, p = 0.47)
Scar group analysis
Less than 4 segments scar group (A) versus ≥ 4 segments
scar group (B)
The baseline characteristics (Table 2) were similar except
that patients in group B had a higher proportion of his-
tory of prior CABG (14 % vs. 1.5 % p = 0.009) and lower
proportion of history of ACE inhibitor usage (47 % ver-
sus 70 % (p = 0.0066)) compared to patients in group A.
There was no statistically significant difference in STS
scores or LVEF between the two groups. The median
number of segments of LGE was 2 (1, 3) for patients in
group A vs. 6 (5, 7) in group B. The number of trans
mural segments was 1(0,2) vs. 2(1,5), p < 0.0001) and the
LVSS was 1.2(1.1,1.3) vs. 1.5(1.4,1.7) p < 0.0001) in group
A vs. group B respectively. During the follow up 27 %
patients died in group A vs. 47 % group B (p = 0.02).
In a univariate analysis (Table 3) Age, LVEF, Female
gender, presence of peripheral artery disease (PAD),
GFR, and Scar group (A vs. B), number of segments
of scar, number of transmural segments and LVSS
were all significantly associated with long-term mortality.
In multivariate analysis (Table 4) Scar group B was inde-
pendently associated with long-term mortality (p = 0.018,
HR = 2.0 (1.1–3.7). Age, LVEF and GFR were also inde-
pendently associated with long-term mortality. Survival
(Fig. 3) was significantly lower in group B compared to
group A (p = 0.038)
LV scar score and long-term mortality
Number of segments of scar (p = 0.005, HR = 1.16 CI =
1.05–1.28), Number of Trans mural segments (p = 0.001,
HR = 1.2 CI = 1.07–1.33) and LVSS (p = 0.0008, HR = 4.9
CI = 1.9–12.3) were independently associated with
long-term mortality. Groups based on LVSS (LVSS 1–1.24
(n = 44), LVSS 1.25–1.42 (n = 43), and LVSS >1.42 (n = 46))
had significantly different survival probabilities (Fig. 4) dur-
ing the follow up (p = 0.026), favoring smaller LVSS.
Discussion
To the best of our knowledge this is the longest survival
follow up after CMR and CABG stratified based on scar
burden. Data was retrievable in 94.4 % of our study
population accurately. The study population had a long-
term mortality of 35 % over a period of 8.3 years. In
prior studies including patients with ischemic cardiomy-
opathy (EF 26–29 %) and CABG, mortality ranged from
Fig. 2 Survival probabilities between No scar and Scar group
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29–58 % over 10 years [19, 20]. In previous studies, pa-
tients with ischemic HF who had CMR, mortality was
15 % over a follow up of 2.6 years [10] and 41 % over a
follow up of 5.8 years [23]. Our patient group had a
moderately reduced LVEF (median 38 %), an increased
prevalence of prior MI, and a longer follow up with
comparable mortality to prior studies.
In our study, there was no significant difference in sur-
vival based on presence or absence of scar. The most
common reason for ordering CMR prior to formulating
treatment strategy in patients with angiographically
significant CAD is for assessment of scar/viability. Myo-
cardial viability however, is a complex and incompletely
understood phenomenon. In clinical practice, the pres-
ence of visually significant CAD on angiography in pa-
tients with cardiomyopathy is equated as ischemic
cardiomyopathy. Previous studies on patients with ische-
mic versus non-ischemic cardiomyopathies have shown
that the extent of CAD is the most predictive feature of
prognosis [24]. However, this may not be the case in all
patients, and in a subgroup of patients with obstructive
CAD, there may be a concomitant non-ischemic etiology
for cardiomyopathy. CMR may be useful in identifying
this subgroup. In our study, patients with no scar had
significantly lower prevalence of prior MI as well as a
lower median number of totally occluded major epicar-
dial arteries compared to the scar group. While no scar
on CMR may indicate that all segments are viable in
these patients, it may alternately suggest a non-ischemic
cardiomyopathy as the primary etiology. This may sug-
gest the need for further analysis to prove ischemia in
this group of patients undergoing CABG, and further
study of non-scar patients to evaluate them for intrinsic
myocardial abnormalities. The current study is limited
by ischemia data acquired before the clinical decision for
CABG was made and the control arm to identify the
Table 2 Baseline characteristics among Scar groups at the time of CABG
Parameter <4 segments - Group A (Mean/Median (IQ)/% ≥4 segments - Group B Mean/Median (IQ)/% p value
Number 67 66
Age (Years) 63.3 (11.2) 62.3 (13.2) 0.69
Male (%) 76.1 80.3 0.56
Body Mass Index (BMI) 28.4 (4.7) 28.4 (4.9) 0.98
History Of Smoking (%) 62.7 68.2 0.51
Diabetes Mellitus (%) 38.8 37.9 0.91
Hypertension (%) 79.1 78.8 0.97
History of Prior MI (%) 74.6 72.7 0.81
Cerebrovascular Disease (%) 14.9 12.1 0.64
Peripheral artery disease (%) 14.9 22.7 0.25
Dyslipidemia (%) 71.6 74.2 0.74
Previous CABG (%) 1.5 13.6 0.009
Glomerular filtration rate (GFR) 68.9 (22.0) 69.6 (28.0) 0.87
Chronic Lung Disease (%) 19.4 13.6 0.37
B – Blocker (%) 85.1 77.3 0.2495
ACE - Inhibitor (%) 70.2 47.0 0.0066
Aspirin (%) 92.5 93.9 1.000
Lipid Lowering Therapy (%) 68.4 83.3 0.0914
LVEDV (ml) 206.8 (73.5) 226.7 (73.0) 0.1237
LVESV (ml) 129.4 (71.6) 151.3 (72.9) 0.0847
LVEF(%) 39 (28,52) 35 (26,45) 0.12
Number of Segments scar 2 (1,3) 6 (5,7) <0.0001
Number of trans mural segments 1 (0, 2) 2 (1,5) <0.0001
Scar score 1.19 (1.13,1.25) 1.50 (1.38,1.75) <0.0001
STS % mortality risk 1.40 (0.66,3.59) 1.46 (0.79,2.69) 0.90
Cardiopulmonary Bypass Used (%) 62.7 66.7 0.6312
Number of vessels bypassed 4 (2–5) 3 (3–4) 0.5929
MI myocardial infarction, ACE angiotensin converting enzyme, CABG coronary artery bypass graft surgery, LVEDV left ventricular end diastolic volume, LVESV left
ventricular end-systolic volume, STS society of thoracic surgeons, LVEF left ventricular ejection fraction
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subgroup of patients with in the no scar group that may
have benefited from revascularization.
In the scar group patients, a higher scar burden is
negatively associated with survival despite CABG. Sev-
eral factors could explain this. Prior studies suggested
that there could be a scar threshold beyond which the
benefits of revascularization are attenuated. It is possible
that patients with large amount of scar in the revascular-
ized territory may actually not have significant viable tis-
sue that can be recovered. In addition, previous studies
have shown that myocardial scar size and characteristics
predict spontaneous ventricular arrhythmias in patients
with an ischemic cardiomyopathy [25–28] which can re-
sult in worse survival independent of LV functional im-
provement. In this study we have used several easily
reproducible parameters to assess scar burden. Number
of segments of scar and number of segments with sig-
nificant transmurality of scar are easy to measure and
are independently associated with long term mortality,
but they may have potential for underestimating and
sometimes overestimating global scar burden. To over-
come this we have used LV scar score, another param-
eter which is easy to measure and a better index of
global scar burden. LVSS also is independently
associated with survival. While the scar group was sub-
divided based on study sample size and previously avail-
able data, it is somewhat arbitrary. However, the overall
study results in the entire scar group strongly suggest a
worse prognosis with increased scar burden. The favor-
able prognosis of patients with small scar burden likely
represents patients with proven ischemic CM who then
obtain the full benefit of revascularization.
Clinical implications
Multiple prior studies suggest worse outcomes and sur-
vival in patients with LGE on CMR. There is data to
support functional improvement after CABG [15–18].
CABG aims to improve symptoms, LVEF, MACE and
prolong survival by reducing ischemia. Data from obser-
vational studies suggest significant survival advantage
from CABG over medical therapy in this patient popula-
tion. The STICH (Surgical Treatment For Ischemic heart
failure) study failed to show improvement in all-cause
mortality but there was a decrease in cardiovascular
death with CABG [21]. LGE on CMR provides unique
long-term prognostic information after CABG, inde-
pendent of traditional predictors. Randomized studies
comparing therapeutic alternatives using CMR viability
data would be needed to determine the utility of this in-
formation in deciding on treatment strategy. The study
used simplified quantification tools to calculate fibrosis
burden based on prior published data, to allow a quick
and day to day estimation of LGE and prognostication in
clinical medicine.
Study limitations
There are several limitations for this study. This study
is a retrospective observational design at a single cen-
ter. As patients were referred by treating physicians,
there could be potential for referral bias in a tertiary
care setting and thus the results may not be general-
ized to all patients undergoing CABG. Patients, in
whom the treating physician favored medical therapy
after reviewing the CMR results, likely those with
large scar area, would not have been evaluated in this
study leading to a selection bias. The data on ische-
mia is not available in these patients which could
have added more clarity to the outcomes in different
subgroups. The currently ongoing Ischemia study may
provide more understanding in this regard. Change of
contrast agent during the study period could poten-
tially effect the LGE quantification; however, to the
best of our knowledge this effect is minimal and is
uniform between different subgroups in the study.
Cause of death was not identified in our study. While
it is possible that deaths could have occurred from
non-cardiovascular causes, we believe that it is more
meaningful to study all-cause mortality for patient
Table 4 Scar group – Cox proportional hazard model,
multivariate analysis with long-term mortality
Parameter p value HR CI
Segment group (≥4) 0.0187 2.035 1.126–3.681
Age 0.0002 1.061 1.029–1.095
LVEF 0.0063 0.969 0.948–0.991
Gender (Female) 0.1811 1.545 0.817–2.922
Peripheral artery disease(PAD) 0.2651 1.483 0.742–2.965
Glomerular filtration rate(GFR) 0.0132 0.989 0.967–0.996
Table 3 Scar group – Cox proportional hazard model, univariate
analysis with long-term mortality
Parameter p value HR CI
Age <0.0001* 1.067 1.037–1.098
Female gender 0.0346* 1.927 0.049–3.541
Peripheral artery disease(PAD) 0.0319* 2.014 1.062–3.816
Glomerular filtration rate(GFR) 0.0003* 0.978 0.966–0.990
LVEF% 0.0079* 0.973 0.954–0.993
Number of segments 0.0040* 1.164 1.049–1.291
Segment group (≥4) 0.0416* 1.830 1.02–3.3
Scar score 0.0016* 4.435 1.756–11.202
Number of trans mural segments 0.0042* 1.174 1.052–1.310
STS mortality risk <0.0001* 1.182 1.20–1.248
MI Myocardial infarction, ACE Angiotensin converting enzyme, CABG Coronary
artery bypass graft surgery, LVEDV Left ventricular end diastolic volume, LVESV
Left Ventricular End-Systolic Volume, STS society of thoracic surgeons. Asterisk
represents variables with significant association
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Fig. 3 Survival probabilities between <4 segment scar and ≥ 4 segments scar groups
Fig. 4 Survival probabilities between Scar groups based on LVSS (LVSS 1–1.24, LVSS 1.25–1.42 and LVSS >1.42)
Kancharla et al. Journal of Cardiovascular Magnetic Resonance  (2016) 18:45 Page 7 of 9
outcomes. In addition, retrospective identification of
cause of death can be highly inaccurate and can ad-
versely affect interpretation of results [29]. Data was
not available in 5.6 % of the study group patients and
is unlikely to alter the results of the study.
Conclusions
In patients undergoing CABG for significant CAD
and have myocardial scar by CMR, the amount of
scar is negatively associated with survival, independ-
ent of traditional predictors. Patients with significant
CAD but without CMR evidence of MI had no statis-
tically significant difference in survival after CABG
compared to those with scar.
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